Compare Repligen Corporation Common Stock (RGEN) vs Western Alliance Bancorporation (WAL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Repligen Corporation Common Stock vs Western Alliance Bancorporation — how do they compare? Repligen Corporation Common Stock trades at $178.15 (market cap $11.14B), while Western Alliance Bancorporation trades at $72.03 (market cap $8.04B). The key difference: Repligen Corporation Common Stock is the larger of the two by market cap, and Western Alliance Bancorporation pays a 2.28% dividend while Repligen Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Repligen Corporation Common Stock for 0 Days and Western Alliance Bancorporation for 3 Days on average.
| RGEN | WAL | |
|---|---|---|
Market Cap | $11.14B | $8.04B |
Volume | 1,259,263 | 1,433,355 |
Sector | Health | Financials |
52-Week High | $194.57 | $96.08 |
52-Week Low | $102.87 | $66.70 |
Typical Hold Time | 0 Days | 3 Days |
Enterprise Value | $11.02B | $9.57B |
Dividend Yield | — | 2.28% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Western Alliance Bancorporation (WAL) trades at $73.73, down 1.29% on the day, reflecting a bearish technical signal despite strong fundamentals. The stock shows solid profitability with a 25.43% net income margin and attractive valuation ratios, including a P/E of 8.32. Recent earnings have mostly beaten estimates, and the company launched WA VenueX, a new financial platform. Analyst consensus is strongly bullish with a $85.09 price target, though technical indicators point to near-term weakness.
The outlook for WAL is positive based on fundamentals and analyst support, but technical headwinds and interest rate sensitivity pose risks. Upside potential exists if the stock rebounds from support levels and executes on growth initiatives, while downside could stem from macroeconomic pressures or missed earnings. The high institutional ownership and recent dividend announcement signal confidence in long-term value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →About Western Alliance Bancorporation
Western Alliance Bancorporation is a top-performing bank holding company that operates a dual business model: high-touch regional banking and specialized national business lines. It serves niche industries—including technology, life sciences, and homeowners associations—providing sophisticated commercial lending and treasury solutions that bridge the gap between regional service and national scale.
Read more on WAL →
